* Q3 EEs 2.7m, down 23% y-o-y, sales SEK 23.5m, down 28% * Softening commercial vehicle market drive...
* '25e-'27e adj. EBITA up 12-5% * Encouraging efficiency improvements and strategic initiatives * Tr...
Redeye updates its estimates and valuation after Relais’ Q3 2025 report.
Active Biotechs styrelse har beslutat om nyemission av aktier för minst 70 mkr.
Redeye provides a preview of its estimates ahead of BICO’s Q3 results, scheduled for release on Nove...
Consti reports its Q3 results on October 24th. We expect the improved backlog to support continued g...
* '25e-'27e sales cut by 20-14% on sluggish market and delayed orders * Rights issue of ~SEK 87m ann...
* 2% sales beat & adj. EBIT SEK 45m vs. ABGSCe 29m * Announces restructuring programme of SEK 20m p.
Q3 report on Thursday, 23 October at 12:00 CET* '25e-'27e adj.
Redeye updates on EG7 ahead of Q3-results (due November 11) where we expect stable quarter with simi...
Ependion’s Q3 report reflects a continued hesitant market and a flattish topline.
Redeye updates its Base Case and forecasts for Lime following the Q3 report.
Redeye leaves a short comment on Xspray following today's news that the FDA has accepted its NDA for...
Relais announced today that Christian Johansson Gebauer, former head of Ratos Construction & Service...
Finnair reports Q3 results on Oct 30. In our view the underlying Q3 results could already be relativ...
* Sales SEK 14m vs. ABGSCe 10m, EBIT in line at SEK -12m * No machine deliveries in the quarter (in ...
Redeye sees a solid report from Lime. While the numbers were slightly below our expectations, the ye...
Redeye provides its initial take on Indutrade’s Q3 2025 report, which beat our profit estimates desp...
Redeye lowers its forecast following softer-than-expected Q3’25 figures.
Redeye is positive about the updated data from Paxman’s CIPN clinical trial in Singapore.